ABA-101 / Abata Therap - LARVOL DELTA

ABA-101 in Participants with Progressive Multiple Sclerosis (clinicaltrials.gov) - P1 | N=12 | Recruiting | Sponsor: Abata Therapeutics | Not yet recruiting ➔ Recruiting

Enrollment open • CNS Disorders • Multiple Sclerosis

ABA-101 in Participants With Progressive Multiple Sclerosis (clinicaltrials.gov) - P1 | N=12 | Not yet recruiting | Sponsor: Abata Therapeutics

New P1 trial • CNS Disorders • Multiple Sclerosis

Abata Therapeutics Receives FDA Fast Track Designation for ABA-101 for the Treatment of Progressive Multiple Sclerosis (GlobeNewswire) - "Abata Therapeutics...announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for ABA-101 for the treatment of patients with progressive multiple sclerosis (MS)."

Fast track • Multiple Sclerosis

Abata Therapeutics Announces Strategic Investment from Bristol Myers Squibb Supporting Advancement of its Treg Cell Therapy Pipeline into Clinical Development (GlobeNewswire) - "Abata Therapeutics...announced it has received an equity investment from Bristol Myers Squibb to support the development of its Treg cell therapy products. Their investment supports Abata's continued advancement into the clinic, with trial initiation imminent for ABA-101 in progressive multiple sclerosis."

Financing • Multiple Sclerosis

Abata Therapeutics Announces FDA Clearance of Investigational New Drug Application for Clinical Evaluation of ABA-101 in Progressive Multiple Sclerosis (GlobeNewswire) - "Abata Therapeutics...announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application to initiate the first-in-human (FIH) Phase 1 study of ABA-101 in patients with progressive multiple sclerosis (MS)....'We look forward to initiating our Phase 1 study later this year in patients and evaluating the potential impact of ABA-101'..."

IND • New P1 trial • Multiple Sclerosis

Abata Therapeutics Announces First Development Candidate, ABA-101, a Novel Treg Cell Therapy for the Treatment of Progressive Multiple Sclerosis (Businesswire) - "ABA-101 is currently in IND-enabling studies and on track to enter the clinic in 2024....Abata Therapeutics...today announced that it has chosen its first development candidate, ABA-101, which has the potential to benefit 45,000 progressive multiple sclerosis (MS) patients in the U.S. who have no treatment options today....“At ElevateBio, we enjoy collaborating with scientific innovators like Abata...We look forward to the continued partnership....Additionally, EAE (experimental autoimmune encephalomyelitis) mouse studies demonstrate proof of biology, including TCR-Treg trafficking, persistence, biological activity, and suppression of inflammation – all critical elements for a successful treatment."

IND • Licensing / partnership • Preclinical • Multiple Sclerosis